JPWO2021021563A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021021563A5
JPWO2021021563A5 JP2022503935A JP2022503935A JPWO2021021563A5 JP WO2021021563 A5 JPWO2021021563 A5 JP WO2021021563A5 JP 2022503935 A JP2022503935 A JP 2022503935A JP 2022503935 A JP2022503935 A JP 2022503935A JP WO2021021563 A5 JPWO2021021563 A5 JP WO2021021563A5
Authority
JP
Japan
Prior art keywords
composition
pharmaceutically acceptable
solvate
acceptable salt
lenvatinib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022503935A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022542238A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/043274 external-priority patent/WO2021021563A1/fr
Publication of JP2022542238A publication Critical patent/JP2022542238A/ja
Publication of JPWO2021021563A5 publication Critical patent/JPWO2021021563A5/ja
Pending legal-status Critical Current

Links

JP2022503935A 2019-07-26 2020-07-23 疾患の予防または治療に有用な官能化長鎖炭化水素モノカルボン酸及びジカルボン酸 Pending JP2022542238A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962878852P 2019-07-26 2019-07-26
US62/878,852 2019-07-26
US201962901739P 2019-09-17 2019-09-17
US62/901,739 2019-09-17
PCT/US2020/043274 WO2021021563A1 (fr) 2019-07-26 2020-07-23 Acides monocarboxyliques et dicarboxyliques d'hydrocarbure à chaîne longue fonctionnalisés utiles pour la prévention ou le traitement d'une maladie

Publications (2)

Publication Number Publication Date
JP2022542238A JP2022542238A (ja) 2022-09-30
JPWO2021021563A5 true JPWO2021021563A5 (fr) 2023-08-16

Family

ID=74189909

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022503935A Pending JP2022542238A (ja) 2019-07-26 2020-07-23 疾患の予防または治療に有用な官能化長鎖炭化水素モノカルボン酸及びジカルボン酸

Country Status (12)

Country Link
US (6) US11098002B2 (fr)
EP (1) EP4003314A4 (fr)
JP (1) JP2022542238A (fr)
KR (1) KR20220039754A (fr)
CN (1) CN114126593A (fr)
AU (1) AU2020321945A1 (fr)
BR (1) BR112022000993A2 (fr)
CA (1) CA3143294C (fr)
IL (1) IL289919A (fr)
MX (1) MX2022000570A (fr)
TW (1) TW202118750A (fr)
WO (1) WO2021021563A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202245804A (zh) 2021-01-25 2022-12-01 美商艾斯佩維他治療學公司 官能化長鏈烴單羧酸及二羧酸及其衍生物以及其於預防或治療疾病之用途
CA3209453A1 (fr) * 2021-01-25 2022-07-28 Espervita Therapeutics, Inc. Acides monocarboxyliques et dicarboxyliques a chaine longue fonctionnalises et leurs derives, et leur utilisation pour la prevention ou le traitement d'une maladie
BR112023017126A2 (pt) * 2021-02-26 2023-12-12 Obi Pharma Inc Uso do composto ativado por akr1c3
CN115887435A (zh) * 2021-09-23 2023-04-04 博骥源（上海）生物医药有限公司 长链类化合物及其用途
CN114736191B (zh) * 2022-04-01 2023-08-08 上海工程技术大学 特普替尼中间体及其制备方法和应用
CN114949230A (zh) * 2022-06-13 2022-08-30 厦门大学附属第一医院 一种预防和/或治疗急性髓系白血病的联合用药物组合物及其应用
CN115844887B (zh) * 2022-12-28 2023-09-08 中国人民解放军空军军医大学 Selonsertib在制备治疗癌症的药物中的用途
CN117843938B (zh) * 2024-03-08 2024-05-24 华东理工大学 一种类聚烯烃的长碳链聚酯弹性体、制备方法及其应用

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US397037A (en) 1889-01-29 Conductor-support
US2789970A (en) 1953-12-08 1957-04-23 Eastman Kodak Co Polycarbonates from 1, 4-bis-(beta-hydroxyethyl)-benzenes-bis
GB900875A (en) 1959-11-12 1962-07-11 Sierra Eng Co Check valve
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
DE2410782C2 (de) 1974-03-07 1982-02-18 Dynamit Nobel Ag, 5210 Troisdorf Phenylendiessigsäuredialkylester und Verfahren zu deren Herstellung
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
IL64542A0 (en) * 1981-12-15 1982-03-31 Yissum Res Dev Co Long-chain alpha,omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
DE3423166A1 (de) 1984-06-22 1986-01-02 Epis S.A., Zug Alpha-, omega-dicarbonsaeuren, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten
ES8702440A1 (es) 1984-10-04 1986-12-16 Monsanto Co Un procedimiento para la preparacion de una composicion de polipeptido inyectable sustancialmente no acuosa.
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5387672A (en) * 1993-03-02 1995-02-07 The University Of Maryland At Baltimore Hemoglobin intramolecularly cross-linked withlong chain divalent reagents
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5648387A (en) 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
AU6242096A (en) 1995-06-27 1997-01-30 Takeda Chemical Industries Ltd. Method of producing sustained-release preparation
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
CA2217134A1 (fr) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Formulation a liberation-retard
ES2221019T3 (es) 1996-10-31 2004-12-16 Takeda Chemical Industries, Ltd. Preparacion de liberacion mantenida.
US6197350B1 (en) 1996-12-20 2001-03-06 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US20020037876A1 (en) 1998-06-25 2002-03-28 Yissum Research Development Company Of Hebrew University Of Jerusalem Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
MXPA01009893A (es) 1999-04-01 2003-07-28 Esperion Therapeutics Inc Compuestos con eter, composiciones y usos de estos.
CA2420535A1 (fr) 2000-08-30 2002-03-07 Mary Tanya Am Ende Formulations a liberation prolongee pour les secretagogues de l'hormone de croissance
US6673780B2 (en) 2000-10-11 2004-01-06 Esperion Therapeutics, Inc. Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
JP2004511453A (ja) 2000-10-11 2004-04-15 エスペリオン　セラピューティクス，インコーポレイテッド コレステロールの制御及び関連する使用のためのケトン化合物及び組成物
US20030236213A1 (en) * 2002-04-10 2003-12-25 Jean-Louis Dasseux Mimics of acyl coenzyme-A comprising pantolactone and pantothenic acid derivatives, compositions thereof, and methods of cholesterol management and related uses
HUE036646T2 (hu) 2003-01-23 2018-07-30 Esperion Therapeutics Inc Hidroxilvegyületek és kompozícióik koleszterin szabályozására és kapcsolódó alkalmazásokra
LT2629776T (lt) 2010-10-18 2017-11-10 Cerenis Therapeutics Holding Sa Junginiai, kompozicijos ir būdai, tinkami cholesterolio mobilizavimui
CN111704543A (zh) 2014-11-14 2020-09-25 燿石治疗公司 用于制备α,ω-二羧酸封端的二烷醚的方法和中间体
CN105801405A (zh) 2016-05-23 2016-07-27 天津迪尔斯化学科技有限公司 一种降血脂小分子化合物、中间体及各自制备方法

Similar Documents

Publication Publication Date Title
Weiss et al. Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies
JP2019530752A (ja) がんを治療するための薬物の調製における、抗ｐｄ‐１抗体とｖｅｇｆｒ阻害剤とを組み合わせた使用
JP2007515469A5 (fr)
WO2004071425A2 (fr) Utilisation combinee d'indoles cruciferes et de chelateurs pour le traitement d'etats lies au papillomavirus
JP6415518B2 (ja) 制御放出粘膜付着システム
JP2012510484A5 (fr)
JP2021509395A5 (fr)
JPWO2021021563A5 (fr)
JP2021523189A (ja) ビスフルオロアルキル−１，４−ベンゾジアゼピノン化合物を含む組成物およびその使用方法
JP2019513828A (ja) 改善された薬物動態を有するイソフラボノイド組成物
AU2006203428B2 (en) Use of 4-pyridylmethylphthalazines for cancer treatment
JP2021523190A (ja) 腺様嚢胞癌を治療するためのビスフルオロアルキル−１，４−ベンゾジアゼピノン化合物を含む組成物
AU2016295357A1 (en) Therapeutic combinations of orally administered paclitaxel and a P-gp inhibitor for the treatment of cancer
TW201127816A (en) 4-methylpyrazole formulations
JP2022088622A (ja) がん療法のためのメトロノミック経口ゲムシタビン
CN112672743A (zh) 肝病瘙痒症状的治疗
JP2022088622A5 (fr)
CN116348094A (zh) 新的胃滞留延长释放剂型
LoRusso et al. Lack of food effect on single-dose pharmacokinetics of brivanib, and safety and efficacy following multiple doses in subjects with advanced or metastatic solid tumors
Vila American Society for Clinical Pharmacology and Therapeutics–123rd Annual Meeting. Virtual–March 16-18, 2022
AU2006221479B2 (en) Method of treating liver cancer
WO2024129619A1 (fr) Inhibiteurs de stat3 destinés à être utilisés dans le traitement du cancer du foie non viral
CN112891510A (zh) 采用iap抑制剂的治疗方法
Haegebarth et al. Potent in vitro and in vivo anti-tumor activity of PI3K inhibitor BAY 80-6946 and MEK inhibitor BAY 86-9766 in preclinical biliary tract cancer models
Sobieraj et al. Focus on... Bazedoxifene: An investigational selective estrogen receptor modulator for the treatment and prevention of osteoporosis in postmenopausal women.